Search results
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
Zacks· 18 hours agoFree Report) . Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important ...
'Smart warheads' of cancer: Experts' excitement for treatment approach grows
Becker’s Hospital Review· 5 days agoCancer experts are increasingly optimistic about the potential for antibody-drug conjugates to become a standard treatment approach. The therapies involve attaching chemotherapy ...
Moderate to intense exercise may boost efficacy of leukemia treatment
Medical News Today· 1 day agoNew research shows that moderate to intense bursts of exercise can aid the efficiency of rituximab,...
Analyst Report: argenx SE
Morningstar Research via Yahoo Finance· 1 day agoArgenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was approved in the U.S. in December ...
FDLI’s Top Cases 2024 Featuring Partner Andrew Wasson | JD Supra
JD Supra· 16 hours agoPartner Andrew Wasson contributed a chapter to the Food & Drug Law Institute’s annual publication identifying the top food and drug cases of the year. Amgen v. Sanofi is undeniably and thoroughly ...
Allergy or infection? Scientists discover what distinguishes these two immune system responses
Medical Xpress· 3 days agoThe production of antibodies, essential for protecting our body against infections, is very well regulated through the action of a specific subtype of immune system cells, follicular helper ...
A promising vaccine approach to induce longer-lasting protective immunity against COVID-19
Medical Xpress· 3 days agoIn an ongoing, four-year collaboration, the team leveraged a novel vaccine platform to fuse the...
Arrivent Biopharma enters into cancer drug development collaboration valued at up to $615M -...
The Business Journals· 2 days agoArriVent, based in Newtown Square, will team with Jiangsu Alphamab Biopharmaceutical to discover and...
I-Mab and BMS assess givastomig for gastric and oesophageal cancer
Pharmaceutical Technology via Yahoo Finance· 2 days agoMyers Squibb (BMS) to assess givastomig in combination with nivolumab plus chemotherapy for advanced...
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
Zacks via Yahoo Finance· 4 days agoARC-9 is a phase Ib/II study evaluating the safety and efficacy of etrumadenant (E), a dual A2a/A2b...